Title : Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells.

Pub. Date : 2021 Sep 25

PMID : 34564697






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Here, we show that combining TKI (imatinib, nilotinib, dasatinib, or asciminib) treatment with the small-molecule MCL1 inhibitor S63845 exerted strong synergistic antiviability and proapoptotic effects on CML lines and CD34+ stem/progenitor cells isolated from untreated CML patients in chronic phase. asciminib MCL1 apoptosis regulator, BCL2 family member Homo sapiens